| Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer V Noronha, VM Patil, A Joshi, N Menon, A Chougule, A Mahajan, A Janu, ... Journal of Clinical Oncology 38 (2), 124-136, 2020 | 369 | 2020 |
| Once-a-week versus once-every-3-weeks cisplatin chemoradiation for locally advanced head and neck cancer: a phase III randomized noninferiority trial V Noronha, A Joshi, VM Patil, J Agarwal, S Ghosh-Laskar, A Budrukkar, ... Journal of Clinical Oncology 36 (11), 1064-1072, 2018 | 318 | 2018 |
| The effects of COVID-19 on perioperative morbidity and mortality in patients with hip fractures: a multicentre cohort study B Kayani, E Onochie, V Patil, F Begum, R Cuthbert, D Ferguson, ... The bone & joint journal 102 (9), 1136-1145, 2020 | 185 | 2020 |
| Synthesis and primary cytotoxicity evaluation of new 5-benzylidene-2, 4-thiazolidinedione derivatives V Patil, K Tilekar, S Mehendale-Munj, R Mohan, CS Ramaa European journal of medicinal chemistry 45 (10), 4539-4544, 2010 | 179 | 2010 |
| Neoadjuvant chemotherapy followed by surgery in very locally advanced technically unresectable oral cavity cancers VM Patil, K Prabhash, V Noronha, A Joshi, V Muddu, S Dhumal, S Arya, ... Oral oncology 50 (10), 1000-1004, 2014 | 146 | 2014 |
| Actionable activating oncogenic ERBB2/HER2 transmembrane and juxtamembrane domain mutations KB Pahuja, TT Nguyen, BS Jaiswal, K Prabhash, TM Thaker, K Senger, ... Cancer cell 34 (5), 792-806. e5, 2018 | 124 | 2018 |
| Lung cancer in the Indian subcontinent V Noronha, R Pinninti, VM Patil, A Joshi, K Prabhash South Asian journal of cancer 5 (03), 095-103, 2016 | 115 | 2016 |
| A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer VM Patil, V Noronha, A Joshi, J Agarwal, S Ghosh‐Laskar, A Budrukkar, ... Cancer 125 (18), 3184-3197, 2019 | 105 | 2019 |
| Low-dose immunotherapy in head and neck cancer: a randomized study VM Patil, V Noronha, N Menon, R Rai, A Bhattacharjee, A Singh, ... Journal of Clinical Oncology 41 (2), 222-232, 2023 | 89 | 2023 |
| A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable … VM Patil, V Noronha, A Joshi, VK Muddu, S Dhumal, B Bhosale, S Arya, ... Oral oncology 51 (3), 279-286, 2015 | 84 | 2015 |
| Micropropagation of pomegranate (Punica granatum L.) ‘Bhagava’ cultivar from nodal explant VM Patil, GA Dhande, DM Thigale, JC Rajput African journal of Biotechnology 10 (79), 18130-18136, 2011 | 75 | 2011 |
| Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group … V Patil, V Noronha, SB Dhumal, A Joshi, N Menon, A Bhattacharjee, ... The Lancet Global Health 8 (9), e1213-e1222, 2020 | 74 | 2020 |
| Evaluation of antihistaminic activity of piper betel leaf in guinea pig R Hajare, VM Darvhekar, A Shewale, V Patil Afr J Pharm Pharmacol 5 (2), 113-117, 2011 | 72 | 2011 |
| Induction chemotherapy in technically unresectable locally advanced oral cavity cancers: does it make a difference? VM Patil, V Noronha, VK Muddu, S Gulia, B Bhosale, S Arya, S Juvekar, ... Indian Journal of Cancer 50 (1), 1-8, 2013 | 70 | 2013 |
| Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma VM Patil, V Noronha, A Joshi, AB Choughule, A Bhattacharjee, R Kumar, ... ESMO open 2 (1), e000168, 2017 | 67 | 2017 |
| Phase I/II study of palliative triple metronomic chemotherapy in platinum-refractory/early-failure oral cancer VM Patil, V Noronha, A Joshi, S Dhumal, M Mahimkar, A Bhattacharjee, ... Journal of clinical oncology 37 (32), 3032-3041, 2019 | 64 | 2019 |
| EGFR mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas? A Joshi, S Zanwar, V Noronha, VM Patil, A Chougule, R Kumar, A Janu, ... OncoTargets and therapy, 1859-1863, 2017 | 63 | 2017 |
| Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis S Kate, A Chougule, A Joshi, V Noronha, V Patil, R Dusane, L Solanki, ... Lung Cancer: Targets and Therapy, 1-10, 2019 | 54 | 2019 |
| Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary management A Rajendra, V Noronha, A Joshi, VM Patil, N Menon, K Prabhash Cancer Research, Statistics, and Treatment 2 (1), 36-53, 2019 | 53 | 2019 |
| Initial experience of a geriatric oncology clinic in a tertiary cancer center in India V Noronha, A Ramaswamy, R Dhekle, V Talreja, V Gota, K Gawit, ... Cancer Research, Statistics, and Treatment 3 (2), 208-217, 2020 | 47 | 2020 |
Vanita NoronhaProfessor, Tata Memorial Hospital在 tmc.gov.in 的电子邮件经过验证
